Nuvalent (NUVL) News Today

Nuvalent, Inc. (NASDAQ: NUVL) appears to be getting a modest lift as investors react to a fresh analyst note from HC Wainwright that still reiterates a Buy rating and a $155 price target, well above where the stock has been trading. That bullish rating is helping offset some concerns from the same report, which included multiple downward revisions to earnings estimates across 2026 through 2030.

• Positive Sentiment: HC Wainwright maintained a Buy rating on Nuvalent and a $155 price target, suggesting meaningful upside from current levels.
• Neutral Sentiment: The analyst introduced or updated several longer-term earnings forecasts, including estimates for 2027-2030, which gives investors more detail on the company’s profit path.
• Negative Sentiment: HC Wainwright lowered near- and medium-term EPS estimates for Nuvalent, including FY2026, FY2027, FY2028, FY2029, and FY2030, which can weigh on sentiment for a development-stage biotech stock.
• Negative Sentiment: The revised forecasts still point to continued losses through 2027, indicating profitability may remain out of reach in the near term.

Overall, NUVL is rising despite the estimate cuts because the analyst’s valuation view remains constructive and implies significant upside potential if the company executes on its pipeline and longer-term earnings outlook.